Current and emerging treatment options for graves' hyperthyroidism

Therapeutics and Clinical Risk Management

Volumn 6, Issue 1, 2010, Pages 29-40

  Abraham, Prakash ^a   Acharya, Shamasunder ^b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b JOHN HUNTER HOSPITAL   (Australia)

Author keywords

Antithyroid drugs; Graves' hyperthyroidism; Methimazole; Propylthiouracil; Radioiodine

Indexed keywords

ANTITHYROID AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIMAZOLE; LEVOTHYROXINE; LITHIUM; LUGOL; NADOLOL; POTASSIUM IODIDE; POTASSIUM PERCHLORATE; PREDNISOLONE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; RITUXIMAB; THIAMAZOLE; WARFARIN;

ADD ON THERAPY; ADJUVANT THERAPY; ADOLESCENT HEALTH; AGRANULOCYTOSIS; ARTHRALGIA; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; EYE DISEASE; FREE THYROXINE INDEX; GASTROINTESTINAL DISEASE; GRAVES DISEASE; HEART ATRIUM FIBRILLATION; HUMAN; IMMUNOMODULATION; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MALIGNANT TRANSFORMATION; PREGNANCY; REVIEW; SHORT COURSE THERAPY; SKIN DISEASE; SMELLING DISORDER; STEROID THERAPY; TASTE DISORDER; THYROID CANCER; THYROID FUNCTION TEST; THYROIDECTOMY; THYROTOXICOSIS; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VASCULITIS; WEIGHT REDUCTION;

EID: 77950871102     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Brent GA. Graves' Disease. N Engl J Med. 2008;358:2594-2605.
2. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid. 2002;12:855-860.
3. Vaidya B, Williams GR, Abraham P, Pearce SHS. Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin Endocrinol (Oxf). 2008;68:814-820.
4. Nayak B, Hodak SP. Hyperthyroidism. Endocrinol Metab Clin N Am. 2007;36:617-656.
5. Cooper D. Antithyroid drugs. N Engl J Med. 2005;352:905-917.
6. Sonnet E, Massart C, Gibassier J, et al. Longitudinal study of soluble intracellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves' disease. J Endocrinol Invest. 1999;22:430-435.
7. Tsatsoulis A, Vlachoyiannopoulos PG, Dalekos GN, et al. Increased serum interleukin-1 beta during treatment of hyperthyroidism with antithyroid drugs. Eur J Clin Invest. 1995;25:654-658.
8. McGregor AM, Peterson MM, Mclachlan SM, et al. Carbimazole and the autoimmune response in Graves' disease. N Engl J Med. 1980;303: 302-307.
9. Jansson R, Dahlberg PA, Johansson H, Lindström B. Intrathyroidal concentrations of methimazole in patients with Graves' disease. J Clin Endocrinol Metab. 1983;57:129-132.
10. Shiroozu A, Okamura K, Ikenoue H, et al. Treatment of hyperthyroidism with a single daily dose of methimazole. J Clin Endocrinol Metab. 1986; 63:125-128.
11. Nicholas WC, Fischer RG, Stevenson RA, et al. Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. South Med J. 1995;88:973-976.
12. Bouma DJ, Kammer H. Single daily dose methimazole treatment of hyperthyroidism. West J Med. 1980;132:13-15.
13. He CT, Hsieh AT, Kuo SW, et al. Comparison of single daily dose methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism. Clin Endocrinol (Oxf). 2004;60:676-681.
14. Benker G, Reinwein D, Kahaly G, et al. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. Clin Endocrinol (Oxf). 1998;49:451-457.
15. Edmonds CJ, Tellez M. Treatment of Graves' disease by carbimazole: high dose with thyroxine compared to titration dose. Eur J Endocrinol. 1994;131:120-124.
16. Goni-Iriarte MJ, Forga Llenas L, Iriarte Berioiz A, et al. Recurrence of Graves-Basedow disease: the influence of treatment schedule. [Spanish]. Medicina Clinica 1995;104:11-14.
17. Grebe SK, Feek CM, Ford HC, et al. A randomized trial of short-term treatment of Graves' disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole. Clin Endocrinol (Oxf). 1998;48: 585-592.
18. Jorde R, Ytre-Arne K, Stromer J, Sundsfjord J. Short-term treatment of Graves' disease with methimazole in high versus low doses. J Intern Med. 1995;238:161-165.
19. Leclere J. Treatment of Basedow disease with synthetic antithyroid drugs. Evaluation of the dose on the efficacy of the long term treatment. [French]. Annales de Endocrinologie 1994;55:11-14.
20. Lucas A, Salinas I, Rius F, et al. Medical therapy of Graves' disease: does thyroxine prevent recurrence of hyperthyroidism? J Clin Endocrinol Metab. 1997;82:2410-2413.
21. McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N Engl J Med. 1996;334:220-224.
22. Nedrebo BG, Holm P, Uhlving S, et al. Graves' disease: drug regimens and predictors of outcome. Eur J Endocrinol. 2002;147: 583-589.
23. Rittmaster RS, Abbott EC, Douglas R, et al. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease. J Clin Endocrinol Metab. 1998;83:814-818.
24. Tuncel E, Ertturk E, Imamoglu S. Effects of Antithyroid drugs alone and plus L-Thyroxine on the relapse of Graves disease. [abstract] J Endocrinol Invest. 2000;7:23.
25. Wilson R, Buchanan L, Fraser WD, McKillop JH, Thomson JA. Do higher doses of carbimazole improve remission in Graves' disease? Q J Med. 1996;89:381-385.
26. Abraham P, Avenell A, Watson WA, Park CM, Bevan JS. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol. 2005;153:489-498.
27. Hashizume K, Ichikawa K, Sakurai A, et al. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med. 1991;324: 947-953.
28. Glinoer D, de Nayer P, Bex M; Belgian Collaborative Study Group on Graves' Disease. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol. 2001;144:475-483.
29. Hoermann R, Quadbeck B, Roggenbuck U, et al; for Basedow Study Group. Relapse of Graves' disease after successful outcome of antithy-roid drug therapy: results of a prospective randomized study on the use of levothyroxine. Thyroid. 2002;12:1119-1128.
30. Mastorakos G, Doufas AG, Mantzos E, Mantzos J, Koutras DA. T4 but not T3 administration is associated with increased recurrence of Graves' disease after successful medical therapy. J Endocrinol Invest. 2003;26:979-984.
31. Allannic H, Fauchet R, Orgiazzi J, et al. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab. 1990;70:675-679.
32. Weetman AP, Pickerill AP, Watsob P, Chatterjee VK, Edwards OM. Treatment of Graves' disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse. Q J Med. 1994;87:337-341.
33. García-Mayor RV, Páramo C, Luna Cano R, Pérez Mendez LF, Galofré JC, Andrade A. Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J Endocrinol Invest. 1992;15:815-820.
34. Maugendre D, Gatel A, Campion L, et al. Antithyroid drugs and Graves' disease prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf). 1999;50:127-132.
35. Takata K, Kubota S, Fukata S, et al. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid. 2009;19: 559-563.
36. Fukata S, Kuma K, Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Thyroid. 1999;9(1):29-31.
37. Harper L, Chin L, Daykin J, et al. Propylthiouracil and carbimazole-associated antineutrophil cytoplasmatic antibodies (ANCA) in patients with Graves' disease. Clin Endocrinol (Oxf). 2004;60:671-675.
38. Mandel S, Cooper DS. The use of antithyroid drugs in pregnancy and lactation. J Clin Endocrinol Metab. 2001;86:2354-2359.
39. Abalovich M, Amino N, Barbour LA, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2007;92(Suppl 2): S1-S47.
40. Azizi F, Ataie L, Hedayati M, Mehrabi Y, Shiekholeslami F. Effect of long-term continuous methimazole treatment of thyrotoxicosis: comparison with radioiodine. Eur J Endocrinol 2005;152:695-701.
41. Walter RM, Bartle WR. Rectal administration of propylthiouracil in the treatment of Graves' disease. Am J Med. 1990;88:69-70.
42. Yeung S, Go R, Balasubramanyam A, et al. Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm. Thyroid. 1995;5:403-405.
43. Nabil N, Miner DJ, Amatruda JM. Methimazole: an alternative route of administration. J Clin Endocrinol Metab. 1982;54:180-181.
44. Jongjaroenprasert W, Akarawut W, Chantasart D, Chailurkit L, Rajatanavin R. Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. Thyroid. 2002;12:627-631.
45. Osman F, Gammage MD, Franklyn JA. Hyperthyroidism and cardiovascular morbidity and mortality. Thyroid. 2002;12:483-487.
46. Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid. 1997;7:163-176.
47. Wartofsky L, Glinoer D, Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan and the United States. Thyroid. 1991;1:129-135.
48. Franklyn JA. The management of hyperthyroidism. N Engl J Med. 1994;330:1731-1738.
49. 131I therapy for Graves' disease. N Engl J Med. 1984;311:426-432.
50. Goolden AW, Stewart JS. Long-term results from graded low dose radioactive iodine therapy for thyrotoxicosis. Clin Endocrinol (Oxf). 1986;24:217-222.
51. Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab. 2002;87:1073-1077.
52. Tamai H, Kasagi K, Takaichi Y, et al. Development of spontaneous hypothyroidism in patients with Graves' disease treated with antithyroidal drugs: clinical, immunological, and histological findings in 26 patients. J Clin Endocrinol Metab. 1989;69:49-53.
53. 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest. 1995;25:186-193.
54. 131I ablation for Graves' disease. J Clin Endocrinol Metab. 2001;86(7):3016-3021.
55. Walter MA, Briel M, Christ-Crain M, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ. 2007;10;334:514.
56. 131in hyperthyroidism. J Clin Endocrinol Metab. 1998;83:685-687.
57. Wilson R, McKillop JH, Buchanan LM, et al. The effect of carbimazole therapy on interleukin 2, interleukin 2 receptor and free radicals. Autoimmunity. 1990;8:3-7.
58. Dunkelmann S, Kunstner H, Nabavi E, Eberlein U, Groth P, Schumichen C. Lithium as an adjunct to radioiodine therapy in Graves' disease for prolonging the intrathyroidal effective half-life of radioiodine. Useful or not? Nuclear-Medizin. 2006;45:213-218; quiz N51-N52.
59. Bogazzi F, Bartalena L, Brogioni S, et al. Comparison of Radioiodine with Radioiodine plus Lithium in the treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab. 1999:84;2:499-503.
60. Jensen BE, Bonnema SJ, Hegedüs L. Glucocorticoids do not influence the effect of radioiodine therapy in Graves' disease. Eur J Endocrinol. 2005;153:15-21.
61. Silva MN, Rubió IG, Romão R, et al. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin Endocrinol (Oxf). 2004;60:300-308.
62. 131I) radiotherapy of Graves disease. Arch Neurol. 2008;65:282-283.
63. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol (Oxf). 2008;69: 943-950.
64. Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA. 2005;294:71-80.
65. Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2001;92:2190-2196.
66. Hall P, Berg G, Bjelkengren G, et al. Cancer mortality after iodine-131 therapy for hyperthyroidism. Int J Cancer. 1992;50:886-890.
67. Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet. 1999;353:2111-2115.
68. Ron E, Doody MM, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA. 1998;280:347-355.
69. Read Jr CH, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab. 2004;89:4229-4233.
70. Royal College of Physicians, UK. Radioiodine in the management of benign thyroid disease. Clinical guidelines. URL: http://www.rcplondon.ac.uk/pubs/brochure.aspx?e=208.
71. Ma C, Kuang A, Xie J, Liu G. Radioiodine treatment for pediatric Graves' disease. Cochrane Database Syst Rev. 2008;(3):CD006294.
72. Sinzinger H, Aiginger P, Neumann I, Havlik E. Radiation alarm at an airport after radioiodine therapy. Nucl Med Commun. 2005;26:67-68.
73. Coyle PJ, Mitchell JE. Thyroidectomy: is Lugol's iodine necessary? Ann R Coll Surg Engl. 1982;64:344-345.
74. Roti E, Robuschi G, Gardini E, et al. Comparison of methimazole, Methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves' disease. Clin Endocrinol (Oxf). 1988;28:305-314.
75. Mercado M, Mendoza-Zubieta V, Bautista-Osorio R, et al. Treatment of hyperthyroidism with a combination of methimazole and cholestyramine. J Clin Endocrinol Metab. 1996;81:3191-3193.
76. Tsai WC, Pei D, Wang T, et al. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism. Clin Endocrinol (Oxf). 2005;62:521-524.
77. Salvi M. Vannucchi G. Campi I, et al. Treatment of Graves' disease and associated opthalmopathy with the anti-CD20 monoclonal antibody rituximab: An open study. Eur J Endocrinol. 2007;156:33-40.
78. El Fassi D, Nielsen CH, Hasselbalch HC, et al. Treatment resistant severe active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid. 2006;16:709-710.
79. El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedus L. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: A controlled pilot study. J Clin Endocrinol Metab. 2007;92:1769-1772.
80. Heemstra KA, Toes RE, Sepers J, et al. Rituximab in relapsing Graves' disease, a phase II study. Eur J Endocrinol. 2008;159:609-615.
81. Stalberg P, Svensson A, Hessman O, Akerstrom G, Hellman P. Surgical Treatment of Graves' Disease: Evidence-Based Approach. World J Surg. 2008;32:1269-1277.
82. Palit TK, Miller CC III, Miltenburg DM. The efficacy of thyroidectomy for Graves' disease: a meta-analysis. J Surg Res 2000;90:161-165.
83. Menconi F, Marino M, Pinchera A, et al. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab. 2007;92:1653-1658.
84. Xiao H, Zhuang W Wang S, et al. Arterial embolization: A nover approach to thyroid ablative therapy for Graves' disease. J Clin Endocrinol Metab. 2002;87:3583-3589.
85. Patel NN, Abraham P, Buscombe J, Vanderpump MPJ. The Cost Effectiveness of Treatment Modalities for Thyrotoxicosis in a UK Centre. Thyroid. 2006;16:593-598.